Skip to main content

Table 2 Comparison of clinical and laboratory indicators between groups (median (lower quartile ~ upper quartile))

From: Correlation between the accumulation of skin glycosylation end products and the development of type 2 diabetic peripheral neuropathy

Variable Grade 0 (n = 79) Grade 1 (n = 199) Grade 2 (n = 202) Grade 3 (n = 80) P
TG (mmol/L) 1.86 (1.13–2.93)c# 1.74 (1.13–2.71)e# 1.57 (1.07–2.40) 1.385 (0.92–2.12) 0.016*
HDL-C (mmol/L) 0.99 (0.82–1.16) 1.015 (0.84–1.16) 1.025 (0.87–1.22) 1.07 (0.93–1.32) 0.069
Cr (μmol/L) 59.1 (48.90–68.20) 63.25 (54.18–76.98)e# 61.95 (51.40–76.28)f## 73.5 (59.53–88.00)c## 0.000*
CysC (mg/L) 0.78 (0.67–0.89)a## 0.935 (0.77–1.21)e## 0.935 (0.80–1.18)bf## 1.09 (0.90–1.47)c## 0.000*
Hcy (μmol/L) 10.03 (7.21–12.47)c## 9.91 (7.81–13.26) 9.77 (8.22–12.88)f## 12.1 (9.55–15.79)e## 0.001*
ACR (mg/g) 12.35 (5.24–33.89)c## 14.46 (5.83–73.43)e# 16.63 (5.62–109.55)f# 51.21 (16.64–296.16) 0.005*
eGFR (ml/min) 109.59 (98.39–120.75) 97.9 (84.92–110.34)ae## 96 (80.98–108.94)bf## 84.84 (64.43–100.41)c## 0.000*
MAU (mg/L) 10.6 (5.34–25.60)c## 11.8 (5.15–62.00)e## 12.65 (4.36–51.03)f## 47.1 (9.39–239.50) 0.001*
α-MG (mg/L) 9.96 (55.25–15.73)c## 12.6 (5.30–25.80) 10.5 (5.01–24.10)f# 19.1 (7.79–34.30) 0.004*
Tf (mg/L) 2 (2.00–2.00)c## 2 (2.00–4.46)e# 2 (2.00–2.92)f## 2.12 (2.00–14.00) 0.000*
U-Ig G (mg/L) 3.75 (3.00–10.19)c## 5.36 (3.00–13.75)e# 4.36 (3.00–11.40)f## 9.15 (4.03–36.10) 0.001*
NEUT(109/L) 3.305 (2.70–4.08) 3.5 (2.70–4.34) 3.62 (2.67–4.52) 3.74 (2.80–4.60) 0.468
LY(109/L) 1.935 (1.45–2.54) 1.66 (1.25–2.17)a# 1.69 (1.25–2.04)b# 1.51 (1.26–1.84)c## 0.001*
NLR 1.64 (1.40–2.24) 2.01 (1.56–2.72)a# 2.13 (1.56–2.86)b## 2.415 (1.69–3.20)c## 0.000*
CRP (mg/L) 0.7 (0.50–1.80) 0.8 (0.50–2.58) 0.9 (0.50–2.60) 1 (0.60–7.60)c# 0.033*
HOMA-IR 1.86 (1.37–6.40) 1.82 (1.18–3.43) 2.005 (1.28–3.07) 0.93 (0.52–1.42) 0.257
PFG (mmol/L) 8.47 (6.38–11.35) 8.3 (6.41–10.17) 7.94 (5.94–10.53) 8.425 (6.25–11.53) 0.394
FINS (mIU/L) 6.78 (3.85–14.75) 7.005 (3.36–10.260 5.84 (3.93–8.59) 3.57 (2.29–4.46) 0.302
C-Peptide (nmol/L) 0.666 (0.45–0.83) 0.7275 (0.48–0.96) 0.646 (0.50–0.87) 0.554 (0.42–0.69) 0.158
2hC-peptide (nmol/L) 1.6 (1.22–2.47) 1.85 (1.29–2.53) 1.59 (1.10–2.10) 1.3 (0.79–2.06) 0.142
HbA1c(%) 9 (7.08–10.48) 8.35 (6.63–11.08) 7.8 (6.70–10.30) 7.35 (6.10–9.88) 0.103
  1. * The progressive significance level was 0.05. Significance of pared comparison after adjustment #P < 0.05; significance of paired comparison after adjustment ##P < 0.01. comparison of grades 0 and 1; comparison between grades 0 and 2; comparison of grades 0 and 3; comparison between levels 1 and 2; comparison between levels 1 and 3; comparison of levels 2 and 3